Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 22, 2026.

The Role of Calcitonin Gene Related Peptide (CGRP) in Neurogenic Vasodilation and Its Cardioprotective Effects

Zizheng Kee, Xenia Kodji, Susan D. Brain

Frontiers in Physiology · 2018 · Review

doi:10.3389/fphys.2018.01249

Abstract

Calcitonin gene-related peptide (CGRP) is a highly potent vasoactive peptide released from sensory nerves, which is now proposed to have protective effects in several cardiovascular diseases. The major α-form is produced from alternate splicing and processing of the calcitonin gene. The CGRP receptor is a complex composed of calcitonin like receptor (CLR) and a single transmembrane protein, RAMP1. CGRP is a potent vasodilator and proposed to have protective effects in several cardiovascular diseases. CGRP has a proven role in migraine and selective antagonists and antibodies are now reaching the clinic for treatment of migraine. These clinical trials with antagonists and antibodies indicate that CGRP does not play an obvious role in the physiological control of human blood pressure. This review discusses the vasodilator and hypotensive effects of CGRP and the role of CGRP in mediating cardioprotective effects in various cardiovascular models and disorders. In models of hypertension, CGRP protects against the onset and progression of hypertensive states by potentially counteracting against the pro-hypertensive systems such as the renin-angiotensin-aldosterone system (RAAS) and the sympathetic system. With regards to its cardioprotective effects in conditions such as heart failure and ischaemia, CGRP-containing nerves innervate throughout cardiac tissue and the vasculature, where evidence shows this peptide alleviates various aspects of their pathophysiology, including cardiac hypertrophy, reperfusion injury, cardiac inflammation, and apoptosis. Hence, CGRP has been suggested as a cardioprotective, endogenous mediator released under stress to help preserve cardiovascular function. With the recent developments of various CGRP-targeted pharmacotherapies, in the form of CGRP antibodies/antagonists as well as a CGRP analog, this review provides a summary and a discussion of the most recent basic science and clinical findings, initiating a discussion on the future of CGRP as a novel target in various cardiovascular diseases.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 22, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Calcitonin gene-related peptide (CGRP) was first identified in 1982. It was soon established that the neuropeptide is a potent vasodilator and a transmitter in the peripheral and central nervous systems, resulting in their predicted roles in pain and cardiovascular regulation. It was soon realized that CGRP release in trigeminal neurons is associated with control of cerebral vascular tone and plays a role in migraine. As such, drugs targeting CGRP are currently being investigated for use clinically for the treatment of migraine. The first non-peptide CGRP antagonist, BIBN 4096 BS, was shown to be effective in animals and humans. There are currently a number of CGRP monoclonal antibodies and antagonists in development which are showing good efficacy for migraine, with up to 32% of patients being completely relieved of symptoms. These drugs are currently undergoing approval for the treatment of migraine. However, as evidence suggests that CGRP possesses protective properties in various cardiovascular diseases, there are concerns regarding cardiovascular safety despite minimal cardiovascular issues being observed in clinical trials to date. This review aims to summarize knowledge on the potential role of CGRP in cardiovascular disease to aid the discussion of potential adverse effects of anti-CGRP treatments as well as to guide the developments of novel CGRP-dependent targets for various cardiovascular conditions.

CGRP Synthesis and Structure

Calcitonin gene-related peptide is a 37 amino acid peptide, produced by alternative splicing of the calcitonin gene (CALCA) (;; Figure 1). Human CGRP exists in α and β forms, which share 94% structural similarity, with different residues at positions 3, 22, and 25. β-CGRP is transcribed from a separate CALCB gene, which has been proposed to be the result of a duplication of the alpha gene. Both α-CGRP and β-CGRP have comparable biological roles, but α-CGRP is the principal form and is found in the central and peripheral nervous systems and is the primary subject of this review, while β-CGRP plays a larger role in enteric transmission. The expression of calcitonin and CGRP mRNA is tissue-specific, and CGRP mRNA is produced by splicing the first three exons to the fifth and sixth exons of CALCA. The translated CGRP protein then undergoes post-translational modification and protease cleavage to generate the mature peptide. This process is illustrated in Figure 1.

Storage, Release and Metabolism

Calcitonin gene-related peptide is localized throughout the peripheral and central sensory nervous system as well as other locations in the brain. Although CGRP is mostly associated with Aδ and C fiber sensory nerves, immunostaining approaches demonstrated the presence of CGRP in association with smooth muscles in the heart and vasculature, suggesting the potential sensory and cardiovascular roles of CGRP. GGRP synthesis mainly occurs in the dorsal root ganglion (DRG) where the pro-peptide is then cleaved to the active form and stored in large dense-core vesicles at the sensory nerve terminals, where CGRP is commonly stored and co-released with substance P. Exocytosis leading to release is mediated by calcium-dependent pathways following nerve depolarization. Although release can be mediated in response to pressor substances, such as the sympathetic noradrenergic transmitter and the hypertensive mediator angiotensin (see section: Hypertension), their release is most commonly associated with the activation of these sensory fibers, either by electrical stimulation or by the activation of transient receptor potential (TRP) channels, as shown in Figure 1. TRP channels are a superfamily of non-selective cation-permeable channels, that are each activated by a range of agonists and stimuli. The precise circumstances under which CGRP is released remain under study. Of particular significance to sensory nerves are TRPV1 (transient receptor potential vanilloid 1) and TRPA1 (transient receptor potential ankyrin 1) channels, which are highly co-expressed in CGRP-positive fibers. TRPV1 is activated by the chili pepper extract capsaicin as well as noxious stimuli such as heat or acidity, acting as transducers of thermal pain, while TRPA1 channels are activated by a distinct subset of agents, including pungent extracts, such as mustard oil and cinnamaldehyde, noxious cold, as well as by endogenous reactive oxygen species and cellular stress mediators. Both TRPV1 and TRPA1 channels have been shown to trigger CGRP release by increasing intracellular calcium levels in vitro and in vivo, producing neurogenic vasodilation. In human skin, capsaicin produces a flare that is mediated by CGRP. TRPV1 was shown to contribute to cardiovascular pathophysiology under certain conditions, such as high fat diet, but not in a CGRP-dependent manner. Moreover, TRPA1 has no observed contribution to blood pressure regulation. The depletion of CGRP positive nerves is possible by repeated TRPV1 agonist application, such as capsaicin and resiniferatoxin, resulting in the desensitization of sensory nerves, which is often used as a blocking strategy. Following its release and action, CGRP has a short half-life, with one study calculating it to have a biphasic clearance with a 6.9-min initial half-life and a 26.4 min slower decay. It is metabolized via proteases and possibly other mechanisms.

CGRP Source and Plasma Levels

The main source of plasma CGRP is thought to be due to a “spillover” from its release from the perivascular nerve endings, which may contribute to its vasodilatory role. Circulating plasma levels in healthy volunteers are low (in the pg/ml range), which in part is due to the rapid metabolic clearance of plasma CGRP. However, CGRP is naturally elevated in pregnancy where it is proposed to regulate utero/placental blood flow and other vascular changes. Plasma levels are elevated in certain pathological states, such as sepsis, where hypotension poses a major comorbidity. In migraine, only cerebral vessel and ipsilateral jugular vein levels, but not plasma levels, of CGRP are elevated. Changes in plasma CGRP levels under pathological conditions are further discussed in respective sections. A range of non-neuronal cells have also been shown to synthesize CGRP, including lymphocytes and monocytes. Endothelial cells have also been shown to synthesize and store CGRP in Weibel-Palade bodies where it may play a role in autoregulation of hemodynamics. Thus, there appear to be multiple sources of CGRP, but the neuronal sources are considered the most important in terms of cardiovascular physiology and pathology and indeed the relevance of some of the cellular sources is unknown.

The CGRP Receptor

The biological effects of CGRP are mainly mediated by its associated receptor. The complex nature of the CGRP receptor has been discussed in-depth recently in. Following an intense period of research, it is now realized that the canonical CGRP receptor is a complex of calcitonin receptor-like receptor (CLR), a class B G-protein coupled receptor (GPCR) and a receptor activity modifying protein 1 (RAMP1), a member of the single transmembrane RAMP family (RAMPs 1, 2, or 3), and the receptor component protein (RCP). RAMP1 is important in the transport of CLR to the plasma membrane where they form a heterodimer to create the full receptor complex and agonist binding, while RCP is important in the intracellular G-protein signaling. However, due to the promiscuous nature of RAMP, it is now thought that CGRP may also be able to signal via other non-canonical receptors of related peptide members, such as the CLR/RAMP3 combination, which is an adrenomedullin receptor (AM2) although at a lower potency. Adrenomedullin additionally has some affinity for CGRP receptors, which could account for some of the heterogeneous results and difficulty in early attempts at classifying the CGRP receptor. This model has been validated experimentally where CGRP binding correlates well to RAMP1 mRNA levels. The RAMP proteins regulate the transport of CLR from the endoplasmic reticulum to the plasma membrane and it has been shown that the cytoplasmic tails of RAMP proteins are crucial for intracellular trafficking of CLR to the membrane. To add to the complexity, more recently it has also been found that association of the calcitonin receptor (CTR) and RAMP1 also forms a CGRP responsive receptor. Although the CTR/RAMP complex was previously described as amylin receptors, it is now shown that CGRP and amylin are equally potent at the CTR/RAMP1 (AMY1) receptor (; Figure 2). Indeed, the expression of CTR/RAMP1 is suggested to be of potential importance in the sensory trigeminal system, where it may play a role in migraine pain as shown by its expression and histology in rats and humans. CTRs can promote RAMP translocation to the cell surface and there may be competition between RAMPs, leading to biased formation of one receptor complex over another. Downstream of the receptor activation, the CGRP receptor complex is coupled to Gαs and Gαq, and the effects of agonist binding are mediated by downstream signaling through these G proteins depending on their sites of action. Using a HEK293 cell line, it was shown that CGRP exhibits biased agonism, favoring the Gαs pathway and thus vasodilation where CGRP triggers nitric oxide (NO) production in the endothelial cells, acting to relax the underlying vascular smooth muscles, while PKA activation in the vascular smooth muscles also independently mediate NO-independent vasodilation by hyperpolarisation of the smooth muscle cell. Thus, while the pharmacological profile of the CLR receptor expressed on the cell surface is dependent on the RAMP subtype that accompanies it, the pharmacology is complex, potentially involving other CGRP receptors.

Vasodilator Effects of CGRP

Physiologically, intravenous infusion of CGRP in humans induces a decrease in blood pressure through its vasodilatory effects as well as a positive chronotropic effect, as demonstrated in humans, in addition to altering regional blood flow, as observed in human subjects. The administration of CGRP by intravenous infusion also increases blood flow to skin (in support of its microvascular potency, resulting in an observable facial flushing) and brain, measured by laser doppler imaging. CGRP can also have effects on other organ systems; for example, in the kidneys, CGRP induced relaxation and increase in cAMP levels result in increased blood flow and a subsequent rise in glomerular filtration that has a significant effect on renal hemodynamics. CGRP also affects coronary blood flow by its direct action on the vasculature, independent of any systemic reflexes due to the changes in blood pressure or heart rate, as measured in humans by angiography. Of note, as discussed above, the vaso-relaxing effects of CGRP do appear to be predominantly at the peripheral level in small vessels rather than large arteries. The highly potent effects of CGRP on multiple cardiovascular functions highlight its potential contribution in various cardiovascular diseases.

CGRP has a range of regulatory effects that have been studied in rodents, as described below. However, it has also been shown to generally mediate its vasodilator activity independently of cyclo-oxygenase products, such as prostacyclin, by comparison, CGRP does have a nitric oxide-dependent vasodilator mechanism in certain tissues in a manner that appears neither species or tissue-dependent. There is also a distinct but reported interaction whereby the CGRP receptor reduces the effects of the potent constrictor agent endothelin through an interaction involving G-protein βγ subunit.

Hypertension

Despite its role as a vasodilator, there is no consensus on the levels of CGRP in hypertension. In human patients with hypertension, plasma CGRP has been found to be higher, unchanged, and decreased as reviewed by several groups (including; ). It has been suggested that these contradictory observations may be due to differences in sampling and radioimmunoassays used as well as due to the heterogeneity in duration, severity, and treatment of the varying hypertensive populations studied. However, in patients with secondary hypertension, plasma CGRP levels were decreased after adrenalectomy to treat the underlying condition. This would indicate that CGRP is a compensatory response to elevated blood pressure and can become depleted or potentially inhibited as disease progresses.

In CGRP knockout (KO) mice, blood pressure was shown to be significantly elevated in some, but not all strains. The role of CGRP has been studied in a range of different rodent models of hypertension. This includes those that involve raising the levels of pressor agent angiotensin. In one study where baseline blood pressure was not affected in CGRP KO mice, angiotensin administration for up to 28 days led to enhanced hypertension, alongside aortic hypertrophy and decreased endothelial nitric oxide synthase expression. In the rat angiotensin-induced hypertension model, the co-administration of subdepressor doses of exogenous CGRP for 6 days significantly reduced blood pressure. However, in a 10-day study, angiotensin increased CGRP receptor expression but not endogenous CGRP levels. In one CGRP KO mouse strain, plasma renin was higher in KO mice and AT1 blockers were found to have greater effects. Thus, there is good evidence that CGRP plays a protective role against the pathophysiology and onset of hypertension. This was further shown in the spontaneously hypertensive rat model, where treatment with angiotensin-converting enzyme inhibitors increased the density of CGRP innervation and expression, restoring CGRP nerve function and vasodilator responses. This adds to the concept that CGRP interacts with RAAS to modulate and maintain blood pressure.

To further understand the mechanisms, deoxycorticosterone (DOC) salt and two-kidney, one-clip (2K1C) rat hypertensive models have been utilized. CGRP expression (mRNA) and plasma levels were elevated, and CGRP8-37 or capsaicin depletion of CGRP (to deplete and thus lose/block the CGRP component) led to further increases in the already elevated blood pressure in these models. In spontaneously hypertensive rats and phenol induced hypertensive models, CGRP expression (mRNA) and plasma levels were instead decreased, but CGRP8-37 or capsaicin pre-treatment had no effect on blood pressure. Hence, it is clear that the loss of CGRP contributes to the development of hypertension.

It is perhaps not surprising that CGRP interacts indirectly with a range of other vasoactive mediators. Early evidence from the rat mesentery indicated that noradrenaline released from sensory nerves could influence release of CGRP and vice versa; indicating the potential of CGRP to be involved in regulating vascular resistance. Immunohistochemical staining revealed high concentrations of CGRP immunoreactive fibers in the rat mesenteric artery, the intensity of which decreased after pre-treatment with capsaicin, confirming the expression of CGRP in this vascular bed. Then, subdepressor doses of CGRP were co-administered with norepinephrine, causing a significant reduction in blood pressure in norepinephrine-induced hypertensive rats. Studies blocking CGRP nerve transmission by CGRP8-37 or capsaicin depletion showed increased vasoconstriction caused by periarterial nerve stimulation, further showing that exogenous CGRP can attenuate noradrenergic-induced constriction. Together, these studies suggest that CGRP has the ability to inhibit sympathetic nervous activity. Indeed, it is considered that perivascular sensory nerves and sympathetic nerves act alongside each other, in rodents at least, to maintain peripheral vascular tone.

Altogether, previous studies have shown that CGRP plays a protective role in the onset and progression of hypertension in rodents. By comparison, the physiological role of CGRP in the normotensive situations in rodents remains unclear, as some knockout mouse strains are mildly hypertensive, indicating a physiological role, as previously mentioned. Usually, these have deletion in the calcitonin gene, in addition to the CGRP, gene. However, the cardiovascular effects of CGRP blockade have been investigated in rat models which found no change in cardiovascular parameters. Hence the evidence mainly from animal models, to date, indicates that CGRP can interact with key pro-hypertensive systems to counterbalance the onset of cardiovascular disease (see Table 1)

Ischemia

CGRP is released endogenously in response to ischemia and is suggested to play a role in preconditioning and protection against reperfusion injury. It has been shown in humans that plasma CGRP expression is upregulated following acute myocardial infarction. In rat models, CGRP induced preconditioning has been shown to be able to protect and attenuate reperfusion injury in heart, brain, and hepatic tissue. These responses were abolished by CGRP8-37, indicating that CGRP is a key central mediator of preconditioning and acts in a protective role. The release of CGRP by TRPV1 is also implicated. In a rat model of ischemia/reperfusion, administration of ruthenium red, a non-selective TRP antagonist, abolished the protective effects of remote limb preconditioning, as measured by infarct size, the release of lactate dehydrogenase, and creatine kinase. The protective effect is also lost with CGRP8-37 administration. This finding is in line with previous studies that have shown plasma CGRP and mRNA levels to be increased after remote limb ischemic preconditioning, suggesting a cardioprotective mechanism involving TRPV1 mediated CGRP release. CGRP also protects against ischemia/reperfusion injury in the liver, as measured by alanine aminotransferase and glutamate-lactate dehydrogenase in one study. A summary is shown in Table 1. However, the mechanism through which CGRP mediates this protective effect remains to be elucidated.

Heart Failure

In the heart, CGRP-containing nerves are densely distributed around the coronary arteries, ventricular muscle, and the conduction system, thus ideally placed to play a functional role in the maintenance of cardiac homeostasis. Reported levels of plasma and tissue CGRP in heart failure, as for hypertension, are confusing and in general, poorly described. One study in children with congenital heart disease found that CGRP levels are higher in those with heart failure compared to healthy controls and levels were also positively correlated with the severity of disease. However, in adult patients with chronic congestive heart failure, CGRP levels were found to be lower. By comparison, increased CGRP levels in blood plasma have been observed in volume overload heart failure in humans, suggesting that it has the potential to act as a compensatory mechanism. In an in vitro model, the administration of the TRPV1 agonist, capsaicin, caused the release of CGRP which had positive inotropic and chronotropic effects on guinea pig atrium that were subject to tachyphylaxis as well as being abolished by capsaicin pre-treatment, to desensitize the nerve. Similar results were observed in a rat model, where CGRP release by another proposed TRPV1 agonist, rutaecarpine, protects against isoprenaline-induced heart failure by relieving cardiac hypertrophy and cardiac apoptosis. These effects were also attenuated with capsaicin pre-treatment, suggesting that CGRP production and release protects against heart failure. This is in keeping with results in the CGRP KO mouse using a transverse aortic constriction (TAC) model. The vasodilator activity of CGRP is considered to decrease cardiac afterload and improve cardiac function. In the guinea pig atrium, CGRP was found to increase the L type calcium current by stimulation of adenylyl cyclase leading to positive inotropy, but the same was not found in ventricular myocytes. This finding is also consistent with earlier studies that showed high binding of radiolabelled CGRP ligands in the rat atrium but not the ventricles and that cAMP levels in the atria significantly increases following administration of CGRP. The effects of CGRP on intracellular calcium dynamics also appear to be mediated by the PI3K/Akt pathway. Inhibition of PI3K in rat myocytes in vivo abolished CGRP induced increases in calcium release and prolonged calcium sequestration. A summary is shown in Table 1.

The concept that exogenous administration of CGRP may be beneficial has been investigated, mainly using the CGRP peptide which, as discussed, has a short half-life. CGRP administration in humans causes an increase in catecholamine levels in the blood, and the inotropic effects of CGRP have been associated with increased plasma norepinephrine and epinephrine. Moreover, the positive inotropy was blocked by adrenergic antagonists but not the hypotensive and chronotropic actions. As heart failure often leads to activation of the baroreceptor reflex and sympathetic activity, the response to CGRP was separated by ganglionic and adrenergic blockade in one canine study. It was found that ganglionic antagonist hexamethonium did not affect CGRP mediated inotropy and vasodilation but the adrenergic antagonist timolol attenuated the heart response to CGRP. Thus, sympathetic activation is suggested to be, at least in part, an indirect effect of CGRP which enhances cardiac function through systemic vasodilation. In a rat coronary ligation model, CGRP was found to have a dilatory effect, but the response to CGRP in the basilar artery was attenuated. This led to the suggestion that this would be beneficial in heart failure as arterial perfusion pressure would be maintained despite the decreased cardiac output. Additionally, in a canine model, CGRP administration increased coronary flow and decreased coronary resistance without affecting heart rate, presumably due to its vasodilatory actions on the coronary vasculature. By comparison, in chronic heart failure, there is attenuation of the adrenergic system. In another canine study, the capacity of sympathetic neurons to release noradrenaline was reduced resulting in reduced sympathetic compensation in heart failure. Additionally, desensitization to catecholamines occurs in multiple points of the adrenoceptor cascade, including decreased distribution and amount of adrenoceptors, decreased agonist affinity, and decreased the activity of adenylyl cyclase. Thus, in chronic heart failure, the indirect sympathetic effects of CGRP are likely to be dampened. It has been suggested that CGRP acts indirectly through sympathetic signaling as a compensatory mechanism to increased demand, such as during exercise where CGRP levels are found to be increased. However, in heart failure where adrenergic transmission becomes downregulated, one possibility may be that CGRP may no longer reduce afterload efficiently to improve cardiac output. Importantly though, CGRP administration has still been shown to be beneficial in the few human studies carried out to date, so more studies are needed.

Effects of CGRP Antagonists and Antibodies That Benefit Migraine on the Baseline Regulation of Human Blood Pressure

Recently, various pharmacological tools targeting CGRP have been developed for the treatment of migraine. CGRP antagonists such as BIBN 4096 BS (Olcegepant) have been used in migraine to good effect but were not further developed despite showing efficacy. Importantly, the safety of these compounds has been studied in single dose and longer-term daily dosing and no cardiovascular adverse events were detected. However, the studies were relatively small and short-term, lasting no more than 12 weeks, as most of the treatments for migraine are administered acutely for short periods of time and the timeframes of clinical studies reflect this. Recently, longer studies involving antibodies have also progressed without cardiovascular side effects. In one study specifically examining cardiovascular and hemodynamic effects of CGRP antagonism in humans, no clinically significant changes in blood pressure, heart rate, or ECG were detected over 24 weeks. There are currently four monoclonal antibodies, against the CGRP peptide or receptor, undergoing phase 2 or 3 clinical trials. At the time of writing, there has not been any cardiovascular adverse event or significant changes in cardiovascular measurements such as electrocardiogram (ECG) attributable to treatment. The findings of the latest trials are detailed (see Table 2). To date, most studies have been performed on normal, healthy subjects and do not address how CGRP blockade may affect a compromised cardiovascular system. Considering the findings in the pre-clinical models consistently showing exacerbation of underlying cardiovascular pathologies with CGRP inhibition it is important to address whether CGRP blockade may exacerbate current cardiovascular disease or increase the severity of cardiovascular events that happen and also whether there is a difference between monoclonal antibodies targeted toward the CGRP receptor or peptide. Emerging evidence begins to take this into account, as a recent clinical study investigated the effect of intravenous erenumab administration in patients with stable angina. Consistently, such acute administration did not show a significant difference in exercise-induced angina or ischemia, consistent with the minimal effect of CGRP inhibition in acute conditions. However, erenumab is currently the only antibody that blocks the CGRP receptor and the results may not be applicable to inhibition of the CGRP ligand. Indeed, further study on whether chronic CGRP depletion adversely affects subjects with cardiovascular disease will be important to establish cardiovascular safety of these drugs, especially as migraine is associated with an increased risk of cardiovascular disease.

CGRP Pharmacotherapy

The administration of a CGRP agonist will act to enhance CGRP signaling and may prove to be beneficial in cardio-protection. As discussed above, CGRP plays several roles in cardio-protection against hypertension, ischemia, and heart failure. Thus, it follows that administration of exogenous CGRP may have beneficial effects in these conditions. However, one of the major drawbacks of CGRP is that, as a peptide, it cannot be delivered orally. In addition, it has a short half-life and is rapidly cleared from the blood. Exogenous CGRP has been studied in patients with congestive heart failure, given by continuous intravenous infusion over 24 h, and has been demonstrated to be beneficial to hemodynamic variables. However, the effects were lost within 30 min of stopping therapy, concurring with the short half-life. Recently, an acylated αCGRP analog has been synthesized and shown to have a significantly longer half-life of 10.2 h using a diabetes model. The same peptide analog was later investigated in murine models of hypertension and heart failure. It was demonstrated that daily dosing with up to 100 nmol/kg protects against hypertension by attenuating cardiac remodeling, oxidative stress, and reduces blood pressure in an Ang-II model of hypertension. Renal function was also preserved, alongside upregulation of RAMP1. In an abdominal aortic constriction model of heart failure, the CGRP analog attenuated cardiac hypertrophy and apoptosis, demonstrating a beneficial effect of chronic CGRP treatment in heart failure over several weeks. In human tissue, this analog also demonstrated similar pharmacological effects to the native peptide, except for a slightly reduced potency but a longer plasma half-life means that it is potentially useful in research as well as therapy. Thus, CGRP analogs or agonism may be a viable pharmacological target for the treatment of cardiovascular diseases and warrants further study.

Future studies should be aimed at understanding the mechanisms involved in the protective effects and the relative contribution of the vasodilator compared with other activities of CGRP described above. It is also hoped that the results targeting the protective effects of CGRP act to incentivise studies into the synthesis of non-peptide CGRP agonists, which could potentially lead to an orally available agonist. This will truly allow the therapeutic potential of CGRP agonists to be evaluated clinically. Meanwhile, the possibility that chronic antagonist and antibody therapy leads to cardiovascular side effects will be evaluated in ongoing experimental medicine studies as well as patient observation of those now being given these new agents to treat migraine.

Conclusion

Calcitonin gene-related peptide is a potent vasodilator peptide released from sensory nerves. While it does not regulate blood pressure or hemodynamics in healthy conditions, it has cardio-protective activities under pathological states. The protective actions of CGRP have been demonstrated in several rodent models of different cardiovascular diseases. CGRP was found to counteract pro-hypertensive systems to protect against hypertension. It remains unclear how important the vasodilator effects are in this. It is also known from studies including those carried out in humans that CGRP decreases afterload and increases inotropy, which is protective in heart failure. Finally, under ischemic stress, CGRP helps preserve cellular energetics, as well as having anti-apoptotic and anti-inflammatory effects. The effects of CGRP on the different pathologies are summarized in Table 1. Ultimately, CGRP is released and confers beneficial protective effects under pathological states.

Currently, CGRP therapy is used in the treatment of migraine, where antagonists and antibody inhibitors have shown good efficacy. No adverse cardiovascular effects of concern have been observed in studies to date. However, many of the safety studies on CGRP antagonists have not examined their effects on subjects with compromised cardiovascular systems. CGRP agonists may have therapeutic use in cardiovascular disorders where they are able to mediate protective actions. However, one of the major hurdles of therapeutic use of CGRP is that, as a peptide, administration and metabolism are issues. Thus, further work on CGRP agonists as therapy for cardiovascular disorders could reveal potential new drugs and provide more options in the treatment of cardiovascular disease.

Author Contributions

ZK and SDB conceptualized and planned the manuscript. ZK wrote the first draft. All authors reviewed, edited, and approved the final version of the manuscript.

Conflict of Interest Statement

SDB is a consultant for Eli Lilly.The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 141

  1. 1.

    Alevizaki M. Shiraishi A. Rassool F. V. Ferrier G. J. MacIntyre I. Legon S. (1986 ). The calcitonin-like sequence of the beta CGRP gene. FEBS Lett. 206 47–52.

    Not in our library10.1016/0014-5793(86)81338-2

  2. 2.

    Al-Rubaiee M. Gangula P. R. Millis R. M. Walker R. K. Umoh N. A. Cousins V. M. (2013 ). Inotropic and lusitropic effects of calcitonin gene-related peptide in the heart. Am. J. Physiol. Heart Circ. Physiol. 304 H1525–H1537.

    Not in our library10.1152/ajpheart.00874.2012

  3. 3.

    Amara S. G. Jonas V. Rosenfeld M. G. Ong E. S. Evans R. M. (1982 ). Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature 298 240–244.

    Not in our library10.1038/298240a0

  4. 4.

    Anand I. S. Gurden J. Wander G. S. O’Gara P. Harding S. E. Ferrari R. (1991 ). Cardiovascular and hormonal effects of calcitonin gene-related peptide in congestive heart failure. J. Am. Coll. Cardiol. 17 208–217.

    Not in our library10.1016/0735-1097(91)90729-s

  5. 5.

    Ashina M. Bendtsen L. Jensen R. Schifter S. Olesen J. (2000 ). Evidence for increased plasma levels of calcitonin gene-related peptide in migraine outside of attacks. Pain 86 133–138.

    Not in our library10.1016/s0304-3959(00)00232-3

  6. 6.

    Aubdool A. A. Kodji X. Abdul-Kader N. Heads R. Fernandes E. S. Bevan S. (2016 ). TRPA1 activation leads to neurogenic vasodilatation: involvement of reactive oxygen nitrogen species in addition to CGRP and NO. Br. J. Pharmacol. 173 2419–2433.

    Not in our library10.1111/bph.13519

  7. 7.

    Aubdool A. A. Thakore P. Argunhan F. Smillie S.-J. Schnelle M. Srivastava S. (2017 ). A novel α-calcitonin gene-related peptide analogue protects against end-organ damage in experimental hypertension, cardiac hypertrophy, and heart failure. Circulation 136 367–383.

    Not in our library10.1161/circulationaha.117.028388

  8. 8.

    Bandell M. Story G. M. Hwang S. W. Viswanath V. Eid S. R. Petrus M. J. (2004 ). Noxious cold ion channel TRPA1 is activated by pungent compounds and bradykinin. Neuron 41 849–857.

    Not in our library10.1016/s0896-6273(04)00150-3

  9. 9.

    Bánvölgyi Á Pálinkás L. Berki T. Clark N. Grant A. D. Helyes Z. (2005 ). Evidence for a novel protective role of the vanilloid TRPV1 receptor in a cutaneous contact allergic dermatitis model. J. Neuroimmunol. 169 86–96.

    Not in our library10.1016/j.jneuroim.2005.08.012

  10. 10.

    Bell D. McDermott B. J. (1996 ). Calcitonin gene-related peptide in the cardiovascular system: characterization of receptor populations and their (patho)physiological significance. Pharmacol. Rev. 48 253–288.

    Not in our library

  11. 11.

    Bergdahl A. Valdemarsson S. Nilsson T. Sun X. Y. Hedner T. Edvinsson L. (1999 ). Dilatory responses to acetylcholine, calcitonin gene-related peptide and substance P in the congestive heart failure rat. Acta Physiol. Scand. 165 15–23.

    Not in our library10.1046/j.1365-201x.1999.00456.x

  12. 12.

    Bigal M. E. Dodick D. W. Rapoport A. M. Silberstein S. D. Ma Y. Yang R. (2015 ). Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 14 1081–1090.

    Not in our library10.1016/s1474-4422(15)00249-5

  13. 13.

    Bigal M. E. Walter S. Bronson M. Alibhoy A. Escandon R. (2014 ). Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP. Cephalalgia 34 968–976.

    Not in our library10.1177/0333102414527646

  14. 14.

    Bodkin J. V. Thakore P. Aubdool A. A. Liang L. Fernandes E. S. Nandi M. (2014 ). Investigating the potential role of TRPA1 in locomotion and cardiovascular control during hypertension. Pharmacol. Res. Perspect. 2:e00052

    Not in our library10.1002/prp2.52

  15. 15.

    Booe J. M. Warner M. L. Roehrkasse A. M. Hay D. L. Pioszak A. A. (2018 ). Probing the mechanism of receptor activity–modifying protein modulation of GPCR ligand selectivity through rational design of potent adrenomedullin and calcitonin gene-related peptide antagonists. Mol. Pharmacol. 93 355–367.

    Not in our library10.1124/mol.117.110916

  16. 16.

    Bracci-Laudiero L. Aloe L. Buanne P. Finn A. Stenfors C. Vigneti E. (2002 ). NGF modulates CGRP synthesis in human B-lymphocytes: a possible anti-inflammatory action of NGF? J. Neuroimmunol. 123 58–65.

    Not in our library10.1016/s0165-5728(01)00475-1

  17. 17.

    Brain S. D. Grant A. D. (2004 ). Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol. Rev. 84 903–934.

    Not in our library10.1152/physrev.00037.2003

  18. 18.

    Brain S. D. Williams T. J. Tippins J. R. Morris H. R. MacIntyre I. (1985 ). Calcitonin gene-related peptide is a potent vasodilator. Nature 313 54–56.

    Not in our library10.1038/313054a0

  19. 19.

    Bühlmann N. Leuthäuser K. Muff R. Fischer J. A. Born W. (1999 ). A receptor activity modifying protein (RAMP)2-dependent adrenomedullin receptor is a calcitonin gene-related peptide receptor when coexpressed with human RAMP1. Endocrinology 140 2883–2890.

    Not in our library10.1210/endo.140.6.6783

  20. 20.

    Cardinal R. Nadeau R. Laurent C. Boudreau G. Armour J. A. (1996 ). Reduced capacity of cardiac efferent sympathetic neurons to release noradrenaline and modify cardiac function in tachycardia-induced canine heart failure. Can. J. Physiol. Pharmacol. 74 1070–1078.

    Not in our library10.1139/y96-112

  21. 21.

    Caterina M. J. Schumacher M. A. Tominaga M. Rosen T. A. Levine J. D. Julius D. (1997 ). The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389 816–824.

    Not in our library10.1038/39807

  22. 22.

    Cernuda-Morollón E. Ramón C. Martínez-Camblor P. Serrano-Pertierra E. Larrosa D. Pascual J. (2015 ). Onabotulinumtoxin a decreases interictal CGRP plasma levels in patients with chronic migraine. Pain 156 820–824.

    Not in our library10.1097/j.pain.0000000000000119

  23. 23.

    Chakravarty P. Suthar T. P. Coppock H. A. Nicholl C. G. Bloom S. R. Legon S. (2000 ). CGRP and adrenomedullin binding correlates with transcript levels for calcitonin receptor-like receptor (CRLR) and receptor activity modifying proteins (RAMPs) in rat tissues. Br. J. Pharmacol. 130 189–195.

    Not in our library10.1038/sj.bjp.0702975

  24. 24.

    Csillik B. Tajti L. Kovács T. Kukla E. Rakic P. Knyihár-Csillik E. (1993 ). Distribution of calcitonin gene-related peptide in vertebrate neuromuscular junctions: relationship to the acetylcholine receptor. J. Histochem. Cytochem. 41 1547–1555.

    Not in our library10.1177/41.10.8245413

  25. 25.

    Deng P.-Y. Li Y.-J. (2005 ). Calcitonin gene-related peptide and hypertension. Peptides 26 1676–1685.

    Not in our library10.1016/j.peptides.2005.02.002

  26. 26.

    Deng P.-Y. Ye F. Cai W.-J. Deng H.-W. Li Y.-J. (2004 ). Role of calcitonin gene-related peptide in the phenol-induced neurogenic hypertension in rats. Regul. Pept. 119 155–161.

    Not in our library10.1016/j.regpep.2004.01.011

  27. 27.

    Deng P.-Y. Ye F. Zhu H.-Q. Cai W.-J. Deng H.-W. Li Y.-J. (2003 ). An increase in the synthesis and release of calcitonin gene-related peptide in two-kidney, one-clip hypertensive rats. Regul. Pept. 114 175–182.

    Not in our library10.1016/s0167-0115(03)00124-1

  28. 28.

    Depre C. Antalik L. Starling A. Koren M. Eisele O. Lenz R. A. (2018 ). A randomized, double-blind, placebo-controlled study to evaluate the effect of erenumab on exercise time during a treadmill test in patients with stable angina. headache. Headache 58 715–723.

    Not in our library10.1111/head.13316

  29. 29.

    Dickerson I. M. (2013 ). Role of CGRP-Receptor Component Protein (RCP) in CLR/RAMP function. Curr. Protein Pept. Sci. 14 407–415.

    Not in our library10.2174/13892037113149990057

  30. 30.

    Dodick D. W. Ashina M. Brandes J. L. Kudrow D. Lanteri-Minet M. Osipova V. (2018a ). ARISE: a Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 38 1026–1037.

    Not in our library10.1177/0333102418759786

  31. 31.

    Dodick D. W. Silberstein S. D. Bigal M. E. Yeung P. P. Goadsby P. J. Blankenbiller T. (2018b ). Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA 319 1999–2008.

    Not in our library10.1001/jama.2018.4853

  32. 32.

    Dodick D. W. Goadsby P. J. Silberstein S. D. Lipton R. B. Olesen J. Ashina M. (2014 ). Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 13 1100–1107.

    Not in our library10.1016/s1474-4422(14)70209-1

  33. 33.

    Doi Y. Kudo H. Nishino T. Kayashima K. Kiyonaga H. Nagata T. (2001 ). Synthesis of calcitonin gene-related peptide (CGRP) by rat arterial endothelial cells. Histol. Histopathol. 16 1073–1079.

    Not in our library10.14670/hh-16.1073

  34. 34.

    Dong Y.-L. Vegiraju S. Gangula P. R. Kondapaka S. B. Wimalawansa S. J. Yallampalli C. (2002 ). Expression and regulation of calcitonin gene-related Peptide receptor in rat placentas. Biol. Reprod. 67 1321–1326.

    Not in our library10.1093/biolreprod/67.4.1321

  35. 35.

    Doods H. Hallermayer G. Wu D. Entzeroth M. Rudolf K. Engel W. (2000 ). Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br. J. Pharmacol. 129 420–423.

    Not in our library10.1038/sj.bjp.0703110

  36. 36.

    Eberhardt M. Stueber T. de la Roche J. Herzog C. Leffler A. Reeh P. W. (2017 ). TRPA1 and TRPV1 are required for lidocaine-evoked calcium influx and neuropeptide release but not cytotoxicity in mouse sensory neurons. PLoS One 12:e0188008

    Not in our library10.1371/journal.pone.0188008

  37. 37.

    Edvinsson L. (2005 ). Clinical data on the CGRP antagonist BIBN4096BS for treatment of migraine attacks. CNS Drug Rev. 11 69–76.

    Not in our library10.1111/j.1527-3458.2005.tb00036.x

  38. 38.

    Edvinsson L. Ekman R. Thulin T. (1989 ). Reduced levels of calcitonin gene-related peptide (CGRP) but not substance P during and after treatment of severe hypertension in man. J. Hum. Hypertens. 3 267–270.

    Not in our library

  39. 39.

    Edvinsson L. Goadsby P. (1995 ). Neuropeptides in the cerebral circulation: relevance to headache. Cephalalgia 15 272–276.

    Not in our library10.1046/j.1468-2982.1995.1504272.x

  40. 40.

    Edvinsson L. Villalón C. M. MaassenVanDenBrink A. (2012 ). Basic mechanisms of migraine and its acute treatment. Pharmacol. Ther. 136 319–333.

    Not in our library10.1007/s13311-017-0592-1

  41. 41.

    Edwards R. M. Trizna W. (1990 ). Calcitonin gene-related peptide: effects on renal arteriolar tone and tubular cAMP levels. Am. J. Physiol. 258 F121–F125.

    Not in our library10.1152/ajprenal.1990.258.1.f121

  42. 42.

    Escott K. J. Brain S. D. (1993 ). Effect of a calcitonin gene-related peptide antagonist (CGRP8-37) on skin vasodilatation and oedema induced by stimulation of the rat saphenous nerve. Br. J. Pharmacol. 110 772–776.

    Not in our library10.1111/j.1476-5381.1993.tb13878.x

  43. 43.

    Evans B. N. Rosenblatt M. I Mnayer L. O. Oliver K. R. Dickerson I. M. (2000 ). CGRP-RCP, a novel protein required for signal transduction at calcitonin gene-related peptide and adrenomedullin receptors. J. Biol. Chem. 275 31438–31443.

    Not in our library10.1074/jbc.m005604200

  44. 44.

    Ferrari R. Panzali A. F. Poole-Wilson P. A. Anand S. (1991 ). Plasma CGRP-like immunoreactivity in treated and untreated congestive heart failure. Lancet 338:1084

    Not in our library10.1016/0140-6736(91)91944-p

  45. 45.

    Franco-Cereceda A. Henke H. Lundberg J. M. Petermann J. B. Hökfelt T. Fischer J. A. (1987 ). Calcitonin gene-related peptide (CGRP) in capsaicin-sensitive substance P-immunoreactive sensory neurons in animals and man: distribution and release by capsaicin. Peptides 8 399–410.

    Not in our library10.1016/0196-9781(87)90117-3

  46. 46.

    Fujioka S. Sasakawa O. Kishimoto H. Tsumura K. Morii H. (1991 ). The antihypertensive effect of calcitonin gene-related peptide in rats with norepinephrine- and angiotensin II-induced hypertension. J. Hypertens. 9 175–179.

    Not in our library10.1097/00004872-199102000-00013

  47. 47.

    Gao Y. Song J. Chen H. Cao C. Lee C. (2015 ). TRPV1 activation is involved in the cardioprotection of remote limb ischemic postconditioning in ischemia-reperfusion injury rats. Biochem. Biophys. Res. Commun. 463 1034–1039.

    Not in our library10.1016/j.bbrc.2015.06.054

  48. 48.

    Gennari C. Fischer J. A. (1985 ). Cardiovascular action of calcitonin gene-related peptide in humans. Calcif. Tissue Int. 37 581–584.

    Not in our library10.1007/bf02554909

  49. 49.

    Gennari C. Nami R. Agnusdei D. Fischer J. A. (1990 ). Improved cardiac performance with human calcitonin gene related peptide in patients with congestive heart failure. Cardiovasc. Res. 24 239–241.

    Not in our library10.1093/cvr/24.3.239

  50. 50.

    Gibbins I. L. Furness J. B. Costa M. MacIntyre I. Hillyard C. J. Girgis S. (1985 ). Co-localization of calcitonin gene-related peptide-like immunoreactivity with substance P in cutaneous, vascular and visceral sensory neurons of guinea pigs. Neurosci. Lett. 57 125–130.

    Not in our library10.1016/0304-3940(85)90050-3

  51. 51.

    Goadsby P. J. Edvinsson L. Ekman R. (1990 ). Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann. Neurol. 28 183–187.

    Not in our library10.1002/ana.410280213

  52. 52.

    Goadsby P. J. Reuter U. Hallström Y. Broessner G. Bonner J. H. Zhang F. (2017 ). A controlled trial of erenumab for episodic migraine. N. Engl. J. Med. 377 2123–2132.

    Not in our library10.1056/nejmoa1705848

  53. 53.

    Gulbenkian S. Merighi A. Wharton J. Varndell I. M. Polak J. M. (1986 ). Ultrastructural evidence for the coexistence of calcitonin gene-related peptide and substance P in secretory vesicles of peripheral nerves in the guinea pig. J. Neurocytol. 15 535–542.

    Not in our library10.1007/bf01611735

  54. 54.

    Hay D. L. Garelja M. L. Poyner D. R. Walker C. S. (2018 ). Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR review 25. Br. J. Pharmacol. 175 3–17.

    Not in our library10.1111/bph.14075

  55. 55.

    Ho T. W. Connor K. M. Zhang Y. Pearlman E. Koppenhaver J. Fan X. (2014 ). Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology 83 958–966.

    Not in our library10.1212/wnl.0000000000000771

  56. 56.

    Hsu J.-H. Yeh J.-L. Dai Z.-K. Chen I.-J. Wu J.-R. (2005 ). Increased circulating calcitonin gene-related peptide in congestive heart failure caused by congenital heart disease. Int. Heart J. 46 867–875.

    Not in our library10.1536/ihj.46.867

  57. 57.

    Ishikawa T. Okamura N. Saito A. Masaki T. Goto K. (1988 ). Positive inotropic effect of calcitonin gene-related peptide mediated by cyclic AMP in guinea pig heart. Circ. Res. 63 726–734.

    Not in our library10.1161/01.res.63.4.726

  58. 58.

    Jäger K. Muench R. Seifert H. Beglinger C. Bollinger A. Fischer J. A. (1990 ). Calcitonin gene-related peptide (CGRP) causes redistribution of blood flow in humans. Eur. J. Clin. Pharmacol. 39 491–494.

    Not in our library10.1007/bf00280942

  59. 59.

    Jancsó N. Jancsó-GáBor A. SzolcsáNyi J. (1967 ). Direct evidence for neurogenic inflammation and its prevention by denervation and by pretreatment with capsaicin. Br. J. Pharmacol. Chemother. 31 138–151.

    Not in our library10.1111/j.1476-5381.1967.tb01984.x

  60. 60.

    Joyce C. D. Fiscus R. R. Wang X. Dries D. J. Morris R. C. Prinz R. A. (1990a ). Calcitonin gene-related peptide levels are elevated in patients with sepsis. Surgery 108 1097–1101.

    Not in our library

  61. 61.

    Joyce C. D. Prinz R. A. Thomas J. X. Fiscus R. R. Wang X. Djuricin G. (1990b ). Calcitonin gene-related peptide increases coronary flow and decreases coronary resistance. J. Surg. Res. 49 435–440.

    Not in our library10.1016/0022-4804(90)90192-5

  62. 62.

    Juhl L. Edvinsson L. Olesen J. Jansen-Olesen I. (2007 ). Effect of two novel CGRP-binding compounds in a closed cranial window rat model. Eur. J. Pharmacol. 567 117–124.

    Not in our library10.1016/j.ejphar.2007.04.004

  63. 63.

    Katori T. Hoover D. B. Ardell J. L. Helm R. H. Belardi D. F. Tocchetti C. G. (2005 ). Calcitonin gene-related peptide in vivo positive inotropy is attributable to regional sympatho-stimulation and is blunted in congestive heart failure. Circ. Res. 96 234–243.

    Not in our library10.1161/01.res.0000152969.42117.ca

  64. 64.

    Kawasaki H. Nuki C. Saito A. Takasaki K. (1990 ). Role of calcitonin gene-related peptide-containing nerves in the vascular adrenergic neurotransmission. J. Pharmacol. Exp. Ther. 252 403–409.

    Not in our library

  65. 65.

    Kawasaki H. Okazaki M. Nakatsuma A. Mimaki Y. Araki H. Gomita Y. (1999 ). Long-term treatment with angiotensin converting enzyme inhibitor restores reduced calcitonin gene-related peptide-containing vasodilator nerve function in mesenteric artery of spontaneously hypertensive rats. Jpn. J. Pharmacol. 79 221–229.

    Not in our library10.1254/jjp.79.221

  66. 66.

    Kawasaki H. Takenaga M. Araki H. Futagami K. Gomita Y. (1998 ). Angiotensin inhibits neurotransmission of calcitonin gene-related peptide-containing vasodilator nerves in mesenteric artery of spontaneously hypertensive rats. J. Pharmacol. Exp. Ther. 284 508–515.

    Not in our library

  67. 67.

    Kobayashi K. Fukuoka T. Obata K. Yamanaka H. Dai Y. Tokunaga A. (2005 ). Distinct expression of TRPM8, TRPA1, and TRPV1 mRNAs in rat primary afferent neurons with adelta/c-fibers and colocalization with trk receptors. J. Comp. Neurol. 493 596–606.

    Not in our library10.1002/cne.20794

  68. 68.

    Kraenzlin M. E. Ch’ng J. L. Mulderry P. K. Ghatei M. A. Bloom S. R. (1985 ). Infusion of a novel peptide, calcitonin gene-related peptide (CGRP) in man. Pharmacokinetics and effects on gastric acid secretion and on gastrointestinal hormones. Regul. Pept. 10 189–197.

    Not in our library10.1016/0167-0115(85)90013-8

  69. 69.

    Kurihara H. Shindo T. Oh-Hashi Y. Kurihar Y. Kuwaki T. (2003 ). Targeted disruption of adrenomedullin and alphaCGRP genes reveals their distinct biological roles. Hypertens. Res. 26(Suppl.), S105–S108.

    Not in our library10.1291/hypres.26.s105

  70. 70.

    Kurtz A. Schurek H. J. Jelkmann W. Muff R. Lipp H. P. Heckmann U. (1989 ). Renal mesangium is a target for calcitonin gene-related peptide. Kidney Int. 36 222–227.

    Not in our library10.1038/ki.1989.183

  71. 71.

    Kuwasako K. Cao Y.-N. Chu C.-P. Iwatsubo S. Eto T. Kitamura K. (2006 ). Functions of the cytoplasmic tails of the human receptor activity-modifying protein components of calcitonin gene-related peptide and adrenomedullin receptors. J. Biol. Chem. 281 7205–7213.

    Not in our library10.1074/jbc.m511147200

  72. 72.

    Li J. Levick S. P. DiPette D. J. Janicki J. S. Supowit S. C. (2013 ). Alpha-calcitonin gene-related peptide is protective against pressure overload-induced heart failure. Regul. Pept. 185 20–28.

    Not in our library10.1016/j.regpep.2013.06.008

  73. 73.

    Li J. Wang D. H. (2005 ). Development of angiotensin II-induced hypertension: role of CGRP and its receptor. J. Hypertens. 23 113–118.

    Not in our library10.1097/00004872-200501000-00020

  74. 74.

    Li J. Zhao H. Supowit S. C. Dipette D. J. Wang D. H. (2004 ). Activation of the renin-angiotensin system in alpha-calcitonin gene-related peptide/calcitonin gene knockout mice. J. Hypertens. 22 1345–1349.

    Not in our library10.1097/01.hjh.0000125409.50839.f1

  75. 75.

    Li J.-Z. Peng J. Xiao L. Zhang Y.-S. Liao M.-C. Li X.-H. (2010 ). Reversal of isoprenaline-induced cardiac remodeling by rutaecarpine via stimulation of calcitonin gene-related peptide production. Can. J. Physiol. Pharmacol. 88 949–959.

    Not in our library10.1139/y10-067

  76. 76.

    Li Y. J. Xiao Z. S. Peng C. F. Deng H. W. (1996 ). Calcitonin gene-related peptide-induced preconditioning protects against ischemia-reperfusion injury in isolated rat hearts. Eur. J. Pharmacol. 311 163–167.

    Not in our library10.1016/0014-2999(96)00426-8

  77. 77.

    Lind H. Brudin L. Lindholm L. Edvinsson L. (1996 ). Different levels of sensory neuropeptides (calcitonin gene-related peptide and substance P) during and after exercise in man. Clin. Physiol. 16 73–82.

    Not in our library10.1111/j.1475-097x.1996.tb00557.x

  78. 78.

    Linscheid P. Seboek D. Schaer D. J. Zulewski H. Keller U. Müller B. (2004 ). Expression and secretion of procalcitonin and calcitonin gene-related peptide by adherent monocytes and by macrophage-activated adipocytes. Crit. Care Med. 32 1715–1721.

    Not in our library10.1097/01.ccm.0000134404.63292.71

  79. 79.

    Liu Z. Liu Q. Cai H. Xu C. Liu G. Li Z. (2011 ). Calcitonin gene-related peptide prevents blood-brain barrier injury and brain edema induced by focal cerebral ischemia reperfusion. Regul. Pept. 171 19–25.

    Not in our library10.1016/j.regpep.2011.05.014

  80. 80.

    Ludman P. F. Maseri A. Clark P. Davies G. J. (1991 ). Effects of calcitonin gene-related peptide on normal and atheromatous vessels and on resistance vessels in the coronary circulation in humans. Circulation 84 1993–2000.

    Not in our library10.1161/01.cir.84.5.1993

  81. 81.

    Lundberg J. M. Franco-Cereceda A. Hua X. Hökfelt T. Fischer J. A. (1985 ). Co-existence of substance P and calcitonin gene-related peptide-like immunoreactivities in sensory nerves in relation to cardiovascular and bronchoconstrictor effects of capsaicin. Eur. J. Pharmacol. 108 315–319.

    Not in our library10.1016/0014-2999(85)90456-x

  82. 82.

    Lundberg J. M. Hua Y. Fredholm B. B. (1984 ). Capsaicin-induced stimulation of the guinea-pig atrium. Naunyn Schmiedebergs Arch. Pharmacol. 325 176–182.

    Not in our library10.1007/bf00506198

  83. 83.

    MaassenVanDenBrink A. Meijer J. Villalón C. M. Ferrari M. D. (2016 ). Wiping out CGRP: potential cardiovascular risks. Trends Pharmacol. Sci. 37 779–788.

    Not in our library10.1016/j.tips.2016.06.002

  84. 84.

    Mai T. Wu J. Diedrich A. Garland E. M. Robertson D. (2014 ). Calcitonin gene related peptide (CGRP) in autonomic cardiovascular regulation and vascular structure. J. Am. Soc. Hypertens. 8 286–296.

    Not in our library10.1016/j.jash.2014.03.001

  85. 85.

    Marshall I. Al-Kazwini S. Holman J. Craig R. (1988 ). Human alpha-calcitonin gene-related peptide (CGRP) is a potent vasodilator in human mesenteric vasculature. Br. J. Clin. Pharmacol. 26 691–695.

    Not in our library10.1111/j.1365-2125.1988.tb05306.x

  86. 86.

    Marshall N. J. Liang L. Bodkin J. Dessapt-Baradez C. Nandi M. Collot-Teixeira S. (2013 ). A role for TRPV1 in influencing the onset of cardiovascular disease in obesity. Hypertension 61 246–252.

    Not in our library10.1161/hypertensionaha.112.201434

  87. 87.

    Masuda A. Shimamoto K. Mori Y. Nakagawa M. Ura N. Iimura O. (1992 ). Plasma calcitonin gene-related peptide levels in patients with various hypertensive diseases. J. Hypertens. 10 1499–1504.

    Not in our library10.1097/00004872-199210120-00010

  88. 88.

    Matteoli M. Haimann C. Torri-Tarelli F. Polak J. M. Ceccarelli B. De Camilli P. (1988 ). Differential effect of alpha-latrotoxin on exocytosis from small synaptic vesicles and from large dense-core vesicles containing calcitonin gene-related peptide at the frog neuromuscular junction. Proc. Natl. Acad. Sci. U.S.A. 85 7366–7370.

    Not in our library10.1073/pnas.85.19.7366

  89. 89.

    McLatchie L. M. Fraser N. J. Main M. J. Wise A. Brown J. Thompson N. (1998 ). RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393 333–339.

    Not in our library10.1038/30666

  90. 90.

    Meens M. J. Mattheij N. J. van Loenen P. B. Spijkers L. J. Lemkens P. Nelissen J. (2012 ). G-protein βγ subunits in vasorelaxing and anti-endothelinergic effects of calcitonin gene-related peptide. Br. J. Pharmacol. 166 297–308.

    Not in our library10.1111/j.1476-5381.2011.01774.x

  91. 91.
    The big CGRP flood - sources, sinks and signalling sites in the trigeminovascular system · 2018
    No notice
  92. 92.

    Mishima T. Ito Y. Hosono K. Tamura Y. Uchida Y. Hirata M. (2011 ). Calcitonin gene-related peptide facilitates revascularization during hindlimb ischemia in mice. Am. J. Physiol. Heart Circ. Physiol. 300 H431–H439.

    Not in our library10.1152/ajpheart.00466.2010

  93. 93.

    Moreno M. J. Terrón J. A. Stanimirovic D. B. Doods H. Hamel E. (2002 ). Characterization of calcitonin gene-related peptide (CGRP) receptors and their receptor-activity-modifying proteins (RAMPs) in human brain microvascular and astroglial cells in culture. Neuropharmacology 42 270–280.

    Not in our library10.1016/s0028-3908(01)00176-9

  94. 94.

    Mulderry P. K. Ghatei M. A. Bishop A. E. Allen Y. S. Polak J. M. Bloom S. R. (1985 ). Distribution and chromatographic characterisation of CGRP-like immunoreactivity in the brain and gut of the rat. Regul. Pept. 12 133–143.

    Not in our library10.1016/0167-0115(85)90194-6

  95. 95.

    Nakajima T. Takikawa R. Sugimoto T. Kurachi Y. (1991 ). Effects of calcitonin gene-related peptide on membrane currents in mammalian cardiac myocytes. Pflugers Arch. 419 644–650.

    Not in our library10.1007/bf00370309

  96. 96.

    Nilsson C. Hansen T. K. Rosenquist C. Hartmann B. Kodra J. T. Lau J. F. (2016 ). Long acting analogue of the calcitonin gene-related peptide induces positive metabolic effects and secretion of the glucagon-like peptide-1. Eur. J. Pharmacol. 773 24–31.

    Not in our library10.1016/j.ejphar.2016.01.003

  97. 97.

    O’Connor T. P. van der Kooy D. (1988 ). Enrichment of a vasoactive neuropeptide (calcitonin gene related peptide) in the trigeminal sensory projection to the intracranial arteries. J. Neurosci. 8 2468–2476.

    Not in our library10.1523/jneurosci.08-07-02468.1988

  98. 98.

    Olesen J. Diener H.-C. Husstedt I. W. Goadsby P. J. Hall D. Meier U. (2004 ). Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N. Engl. J. Med. 350 1104–1110.

    Not in our library10.1056/nejmoa030505

  99. 99.

    Ozaka T. Doi Y. Kayashima K. Fujimoto S. (1997 ). Weibel-Palade bodies as a storage site of calcitonin gene-related peptide and endothelin-1 in blood vessels of the rat carotid body. Anat. Rec. 247 388–394.

    Not in our library10.1002/(sici)1097-0185(199703)247:3<388::aid-ar10>3.0.co;2-l

  100. 100.

    Paemeleire K. MaassenVanDenBrink A. (2018 ). Calcitonin-gene-related peptide pathway mAbs and migraine prevention. Curr. Opin. Neurol. 31 274–280.

    Not in our library10.1097/wco.0000000000000548

  101. 101.

    Portaluppi F. Trasforini G. Margutti A. Vergnani L. Ambrosio M. R. Rossi R. (1992 ). Circadian rhythm of calcitonin gene-related peptide in uncomplicated essential hypertension. J. Hypertens. 10 1227–1234.

    Not in our library10.1097/00004872-199210000-00017

  102. 102.

    Pozsgai G. Hajna Z. Bagoly T. Boros M. Kemény Á Materazzi S. (2012 ). The role of transient receptor potential ankyrin 1 (TRPA1) receptor activation in hydrogen-sulphide-induced CGRP-release and vasodilation. Eur. J. Pharmacol. 689 56–64.

    Not in our library10.1016/j.ejphar.2012.05.053

  103. 103.

    Preibisz J. J. (1993 ). Calcitonin gene-related peptide and regulation of human cardiovascular homeostasis. Am. J. Hypertens. 6 434–450.

    Not in our library10.1093/ajh/6.5.434

  104. 104.

    Qi T. Ly K. Poyner D. R. Christopoulos G. Sexton P. M. Hay D. L. (2011 ). Structure–function analysis of amino acid 74 of human RAMP1 and RAMP3 and its role in peptide interactions with adrenomedullin and calcitonin gene-related peptide receptors. Peptides 32 1060–1067.

    Not in our library10.1016/j.peptides.2011.03.004

  105. 105.

    Quallo T. Gentry C. Bevan S. Broad L. M. Mogg A. J. (2015 ). Activation of transient receptor potential ankyrin 1 induces CGRP release from spinal cord synaptosomes. Pharmacol. Res. Perspect. 3:e00191

    Not in our library10.1002/prp2.191

  106. 106.

    Raffaelli B. Reuter U. (2018 ). The biology of monoclonal antibodies: focus on calcitonin gene-related peptide for prophylactic migraine therapy. Neurotherapeutics 15 324–335.

    Not in our library10.1007/s13311-018-0622-7

  107. 107.

    Rosenfeld M. G. Mermod J.-J. Amara S. G. Swanson L. W. Sawchenko P. E. Rivier J. (1983 ). Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature 304 129–135.

    Not in our library10.1038/304129a0

  108. 108.

    Roudenok V. Gutjar L. Antipova V. Rogov Y. (2001 ). Expression of vasoactive intestinal polypeptide and calcitonin gene-related peptide in human stellate ganglia after acute myocardial infarction. Ann. Anat. 183 341–344.

    Not in our library10.1016/s0940-9602(01)80176-x

  109. 109.

    Russell F. A. King R. Smillie S.-J. Kodji X. Brain S. D. (2014 ). Calcitonin gene-related peptide: physiology and pathophysiology. Physiol. Rev. 94 1099–1142.

    Not in our library10.1152/physrev.00034.2013

  110. 110.

    Sacco S. Kurth T. (2014 ). Migraine and the risk for stroke and cardiovascular disease. Curr. Cardiol. Rep. 16:524

    Not in our library10.1007/s11886-014-0524-1

  111. 111.

    Schifter S. Krusell L. R. Sehested J. (1991 ). Normal serum levels of calcitonin gene-related peptide (CGRP) in mild to moderate essential hypertension. Am. J. Hypertens. 4 565–569.

    Not in our library10.1093/ajh/4.7.565

  112. 112.

    Schlereth T. Schukraft J. Krämer-Best H. H. Geber C. Ackermann T. Birklein F. (2016 ). Interaction of calcitonin gene related peptide (CGRP) and substance P (SP) in human skin. Neuropeptides 59 57–62.

    Not in our library10.1016/j.npep.2016.06.001

  113. 113.

    Sekiguchi N. Kanatsuka H. Sato K. Wang Y. Akai K. Komaru T. (1994 ). Effect of calcitonin gene-related peptide on coronary microvessels and its role in acute myocardial ischemia. Circulation 89 366–374.

    Not in our library10.1161/01.cir.89.1.366

  114. 114.

    Shang S. Zhu F. Liu B. Chai Z. Wu Q. Hu M. (2016 ). Intracellular TRPA1 mediates Ca2+ release from lysosomes in dorsal root ganglion neurons. J. Cell Biol. 215 369–381.

    Not in our library10.1083/jcb.201603081

  115. 115.

    Shekhar Y. C. Anand I. S. Sarma R. Ferrari R. Wahi P. L. Poole-Wilson P. A. (1991 ). Effects of prolonged infusion of human alpha calcitonin gene-related peptide on hemodynamics, renal blood flow and hormone levels in congestive heart failure. Am. J. Cardiol. 67 732–736.

    Not in our library10.1016/0002-9149(91)90531-o

  116. 116.

    Sheykhzade M. Abdolalizadeh B. Koole C. Pickering D. S. Dreisig K. Johansson S. E. (2018 ). Vascular and molecular pharmacology of the metabolically stable CGRP analogue, SAX. Eur. J. Pharmacol. 829 85–92.

    Not in our library10.1016/j.ejphar.2018.04.007

  117. 117.

    Sigrist S. Franco-Cereceda A. Muff R. Henke H. Lundberg J. M. Fischer J. A. (1986 ). Specific receptor and cardiovascular effects of calcitonin gene-related peptide. Endocrinology 119 381–389.

    Not in our library10.1210/endo-119-1-381

  118. 118.

    Singh A. Randhawa P. K. Bali A. Singh N. Jaggi A. S. (2017 ). Exploring the role of TRPV and CGRP in adenosine preconditioning and remote hind limb preconditioning-induced cardioprotection in rats. Cardiovasc. Drugs Ther. 31 133–143.

    Not in our library10.1007/s10557-017-6716-3

  119. 119.

    Smillie S.-J. Brain S. D. (2011 ). Calcitonin gene-related peptide (CGRP) and its role in hypertension. Neuropeptides 45 93–104.

    Not in our library10.1016/j.npep.2010.12.002

  120. 120.

    Smillie S.-J. King R. Kodji X. Outzen E. Pozsgai G. Fernandes E. (2014 ). An ongoing role of α-calcitonin gene–related peptide as part of a protective network against hypertension, vascular hypertrophy, and oxidative stress. Hypertension 63 1056–1062.

    Not in our library10.1161/hypertensionaha.113.02517

  121. 121.

    Song S. W. Guo K. J. Shi R. Cheng Y. Liu Y. F. (2009 ). Pretreatment with calcitonin gene-related peptide attenuates hepatic ischemia/reperfusion injury in rats. Transplant. Proc. 41 1493–1498.

    Not in our library10.1016/j.transproceed.2009.03.056

  122. 122.

    Stauffer V. L. Dodick D. W. Zhang Q. Carter J. N. Ailani J. Conley R. R. (2018 ). Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. [Epub ahead of print].

    Not in our library10.1001/jamaneurol.2018.1212

  123. 123.

    Struthers A. D. Brown M. J. Macdonald D. W. R. Beacham J. L. Stevenson J. C. Morris H. R. (1986 ). Human calcitonin gene related peptide: a potent endogenous vasodilator in man. Clin. Sci. 70 389–393.

    Not in our library10.1042/cs0700389

  124. 124.

    Supowit S. C. Ramana C. V. Westlund K. N. Di Pette D. J. (1993 ). Calcitonin gene-related peptide gene expression in the spontaneously hypertensive rat. Hypertension 21 1010–1014.

    Not in our library10.1161/01.hyp.21.6.1010

  125. 125.

    Supowit S. C. Zhao H. Hallman D. M. DiPette D. J. (1997 ). Calcitonin gene-related peptide is a depressor of deoxycorticosterone-salt hypertension in the rat. Hypertension 29 945–950.

    Not in our library10.1161/01.hyp.29.4.945

  126. 126.

    Takenaga M. Kawasaki H. (1999 ). Endogenous calcitonin gene-related peptide suppresses vasoconstriction mediated by adrenergic nerves in rat mesenteric resistance blood vessels. Eur. J. Pharmacol. 367 239–245.

    Not in our library10.1016/s0014-2999(98)00949-2

  127. 127.

    Taquet H. Komajda M. Grenier O. Belas F. Landault C. Carayon A. (1992 ). Plasma calcitonin gene-related peptide decreases in chronic congestive heart failure. Eur. Heart J. 13 1473–1476.

    Not in our library10.1093/oxfordjournals.eurheartj.a060088

  128. 128.

    Terenghi G. Polak J. M. Ghatei M. A. Mulderry P. K. Butler J. M. Unger W. G. (1985 ). Distribution and origin of calcitonin gene-related peptide (CGRP) immunoreactivity in the sensory innervation of the mammalian eye. J. Comp. Neurol. 233 506–516.

    Not in our library10.1002/cne.902330410

  129. 129.

    Tortorella C. Macchi C. Forneris M. Nussdorfer G. G. (2001 ). Calcitonin gene-related peptide (CGRP), acting via CGRP type 1 receptors, inhibits potassium-stimulated aldosterone secretion and enhances basal catecholamine secretion from rat adrenal gland. Int. J. Mol. Med. 8 261–264.

    Not in our library10.3892/ijmm.8.3.261

  130. 130.

    Van der Schueren B. J. Rogiers A. Vanmolkot F. H. Van Hecken A. Depré M. Kane S. A. (2008 ). Calcitonin gene-related peptide8-37 antagonizes capsaicin-induced vasodilation in the skin: evaluation of a human in vivo pharmacodynamic model. J. Pharmacol. Exp. Ther. 325 248–255.

    Not in our library10.1124/jpet.107.133868

  131. 131.

    Vatner D. E. Sato N. Ishikawa Y. Kiuchi K. Shannon R. P. Vatner S. F. (1996 ). Beta-adrenoceptor desensitization during the development of canine pacing-induced heart failure. Clin. Exp. Pharmacol. Physiol. 23 688–692.

    Not in our library10.1111/j.1440-1681.1996.tb01760.x

  132. 132.

    Venkatachalam K. Montell C. (2007 ). TRP Channels. Annu. Rev. Biochem. 76 387–417.

    Not in our library10.1146/annurev.biochem.75.103004.142819

  133. 133.

    Viana F. (2016 ). TRPA1 channels: molecular sentinels of cellular stress and tissue damage. J. Physiol. 594 4151–4169.

    Not in our library10.1113/jp270935

  134. 134.

    Wang H. Xing L. Li W. Hou L. Guo J. Wang X. (2002 ). Production and secretion of calcitonin gene-related peptide from human lymphocytes. J. Neuroimmunol. 130 155–162.

    Not in our library10.1016/s0165-5728(02)00221-7

  135. 135.

    Wang W. Zhu G.-Q. Gao L. Tan W. Qian Z.-M. (2004 ). Baroreceptor reflex in heart failure. Sheng Li Xue Bao 56 269–281.

    Not in our library

  136. 136.

    Weston C. Winfield I. Harris M. Hodgson R. Shah A. Dowell S. J. (2016 ). Receptor activity-modifying protein-directed g protein signaling specificity for the calcitonin gene-related peptide family of receptors. J. Biol. Chem. 291 21925–21944.

    Not in our library10.1074/jbc.m116.751362

  137. 137.

    Wolfrum S. Nienstedt J. Heidbreder M. Schneider K. Dominiak P. Dendorfer A. (2005 ). Calcitonin gene related peptide mediates cardioprotection by remote preconditioning. Regul. Pept. 127 217–224.

    Not in our library10.1016/j.regpep.2004.12.008

  138. 138.

    Yao G. Yu T. Han X. Mao X. Li B. (2013 ). Therapeutic effects and safety of olcegepant and telcagepant for migraine: a meta-analysis. Neural Regen. Res. 8 938–947.

    Not in our library10.3969/j.issn.1673-5374.2013.10.009

  139. 139.

    Zaidi M. Brain S. D. Tippins J. R. Di Marzo V. Moonga B. S. Chambers T. J. (1990 ). Structure-activity relationship of human calcitonin-gene-related peptide. Biochem. J. 269 775–780.

    Not in our library10.1042/bj2690775

  140. 140.

    Zeller J. Poulsen K. T. Sutton J. E. Abdiche Y. N. Collier S. Chopra R. (2008 ). CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat. Br. J. Pharmacol. 155 1093–1103.

    Not in our library10.1038/bjp.2008.334

  141. 141.

    Zheng J. (2013 ). Molecular mechanism of TRP channels. Compr. Physiol. 3 221–242.

    Not in our library10.1002/cphy.c120001

Cited by papers we hold 3

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.